Evidence map›Paper›PMID 28391636›Full record

ArticleFEBS letters2017

Impaired hypoxic tolerance in APP23 mice: a dysregulation of neuroprotective globin levels.

Zoë P Van Acker, Evi Luyckx, Wendy Van Leuven, Eva Geuens, Peter P De Deyn, Debby Van Dam, Sylvia Dewilde

Open access · bronzeAbstract readLetter
In one paragraph

Article in FEBS letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 2 countries.

Zoë P Van AckerLaboratory of Protein Science, Proteomics and Epigenetic Signalling, Department of Biomedical Sciences, University of Antwerp, Wilrijk, Belgium.
Evi LuyckxLaboratory of Protein Science, Proteomics and Epigenetic Signalling, Department of Biomedical Sciences, University of Antwerp, Wilrijk, Belgium.
Wendy Van LeuvenLaboratory of Protein Science, Proteomics and Epigenetic Signalling, Department of Biomedical Sciences, University of Antwerp, Wilrijk, Belgium.
Eva GeuensLaboratory of Protein Science, Proteomics and Epigenetic Signalling, Department of Biomedical Sciences, University of Antwerp, Wilrijk, Belgium.
Peter P De DeynLaboratory of Neurochemistry & Behaviour, Institute Born-Bunge, Department of Biomedical Sciences, University of Antwerp, Wilrijk, Belgium.
Debby Van DamLaboratory of Neurochemistry & Behaviour, Institute Born-Bunge, Department of Biomedical Sciences, University of Antwerp, Wilrijk, Belgium.
Sylvia DewildeLaboratory of Protein Science, Proteomics and Epigenetic Signalling, Department of Biomedical Sciences, University of Antwerp, Wilrijk, Belgium.
University of Antwerp · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although neuroglobin confers neuroprotection against Alzheimer's disease (AD) pathology, its expression becomes downregulated in late-stage AD. Here, we provide evidence that indicates that this decrease is associated with the AD-linked angiopathy. While wild-type mice of different ages show upregulated cerebral neuroglobin expression upon whole-body hypoxia, APP23 mice exhibit decreased cerebral transcription of neuroglobin. Interestingly, transcription of cytoglobin, whose involvement in amyloid pathology still needs to be elucidated, follows a similar pattern. To further unravel the underlying mechanism, we examined the expression levels of the RE-1-silencing transcription factor (REST/NRSF) after identifying a recognition site for it in the regulatory region of both globins. Neuroglobin-cytoglobin-REST/NRSF expression correlations are detected mainly in the cortex. This raises the possibility of REST/NRSF being an upstream regulator of these globins.

Indexed as

Amyloid beta-Protein PrecursorAnimalsBinding SitesCell HypoxiaCerebral Amyloid AngiopathyCytoglobinDisease Models, AnimalDown-RegulationFrontal LobeGlobinsHumansMiceMice, TransgenicNerve Tissue ProteinsNeuroglobinRE1-Silencing Transcription FactorAmyloid beta-Protein PrecursorAPP protein, humanCYGB protein, humanCygb protein, mouseCytoglobinGlobinsNerve Tissue ProteinsNeuroglobinRE1-Silencing Transcription FactorRepressor ProteinsAPP23cytoglobinhypoxianeuroglobinREST/NRSF

Identifiers

PMID28391636
PMCPMC5518225
OpenAlexW2605365417

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.